News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
729,694 Results
Type
Article (43225)
Company Profile (464)
Press Release (685995)
Multimedia
Podcasts (108)
Webinars (20)
Section
Business (209131)
Career Advice (2032)
Deals (36089)
Drug Delivery (109)
Drug Development (83827)
Employer Resources (174)
FDA (16594)
Job Trends (15166)
News (353704)
Policy (33236)
Tag
Academia (2648)
Accelerated approval (18)
Adcomms (28)
Allergies (120)
Alliances (51111)
ALS (142)
Alzheimer's disease (1615)
Antibody-drug conjugate (ADC) (239)
Approvals (16673)
Artificial intelligence (423)
Autoimmune disease (88)
Automation (29)
Bankruptcy (373)
Best Places to Work (11840)
BIOSECURE Act (20)
Biosimilars (154)
Biotechnology (331)
Bladder cancer (136)
Brain cancer (48)
Breast cancer (499)
Cancer (3940)
Cardiovascular disease (326)
Career advice (1714)
Career pathing (34)
CAR-T (236)
CDC (44)
Cell therapy (640)
Cervical cancer (31)
Clinical research (70053)
Collaboration (1376)
Company closure (4)
Compensation (933)
Complete response letters (51)
COVID-19 (2740)
CRISPR (81)
C-suite (593)
Cystic fibrosis (137)
Data (4718)
Decentralized trials (2)
Denatured (35)
Depression (104)
Diabetes (427)
Diagnostics (6599)
Digital health (34)
Diversity (11)
Diversity, equity & inclusion (45)
Drug discovery (198)
Drug pricing (168)
Drug shortages (29)
Duchenne muscular dystrophy (203)
Earnings (90214)
Editorial (50)
Employer branding (21)
Employer resources (152)
Events (119117)
Executive appointments (957)
FDA (19077)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (6)
Frontotemporal dementia (16)
Funding (1245)
Gene editing (171)
Generative AI (32)
Gene therapy (524)
GLP-1 (913)
Government (4699)
Grass and pollen (6)
Guidances (369)
Healthcare (19188)
HIV (45)
Huntington's disease (38)
IgA nephropathy (63)
Immunology and inflammation (230)
Immuno-oncology (19)
Indications (58)
Infectious disease (2968)
Inflammatory bowel disease (181)
Inflation Reduction Act (16)
Influenza (95)
Intellectual property (192)
Interviews (315)
IPO (16900)
IRA (51)
Job creations (3710)
Job search strategy (1439)
Kidney cancer (15)
Labor market (73)
Layoffs (567)
Leadership (30)
Legal (8014)
Liver cancer (87)
Longevity (11)
Lung cancer (570)
Lymphoma (267)
Machine learning (30)
Management (59)
Manufacturing (608)
MASH (139)
Medical device (13777)
Medtech (13801)
Mergers & acquisitions (20076)
Metabolic disorders (1082)
Multiple sclerosis (135)
NASH (19)
Neurodegenerative disease (218)
Neuropsychiatric disorders (58)
Neuroscience (2628)
NextGen: Class of 2025 (6758)
Non-profit (4563)
Now hiring (59)
Obesity (515)
Opinion (261)
Ovarian cancer (138)
Pain (158)
Pancreatic cancer (171)
Parkinson's disease (236)
Partnered (28)
Patents (408)
Patient recruitment (326)
Peanut (53)
People (59677)
Pharmaceutical (86)
Pharmacy benefit managers (26)
Phase I (21997)
Phase II (30885)
Phase III (22861)
Pipeline (2760)
Policy (260)
Postmarket research (2602)
Preclinical (9448)
Press Release (67)
Prostate cancer (198)
Psychedelics (50)
Radiopharmaceuticals (275)
Rare diseases (652)
Real estate (6045)
Recruiting (70)
Regulatory (23999)
Reports (51)
Research institute (2448)
Resumes & cover letters (353)
Rett syndrome (15)
RNA editing (15)
RSV (67)
Schizophrenia (134)
Series A (207)
Series B (157)
Service/supplier (11)
Sickle cell disease (80)
Special edition (25)
Spinal muscular atrophy (154)
Sponsored (36)
Startups (3789)
State (2)
Stomach cancer (15)
Supply chain (95)
Tariffs (80)
The Weekly (71)
Vaccines (932)
Venture capital (65)
Weight loss (341)
Women's health (57)
Worklife (18)
Date
Today (182)
Last 7 days (756)
Last 30 days (2763)
Last 365 days (31326)
2025 (25966)
2024 (36300)
2023 (41016)
2022 (52277)
2021 (56764)
2020 (54922)
2019 (47416)
2018 (35696)
2017 (33024)
2016 (32349)
2015 (38397)
2014 (32186)
2013 (27109)
2012 (29221)
2011 (29863)
2010 (27992)
Location
Africa (746)
Alabama (77)
Alaska (7)
Arizona (278)
Arkansas (14)
Asia (40149)
Australia (6675)
California (9502)
Canada (2866)
China (892)
Colorado (397)
Connecticut (416)
Delaware (265)
Europe (87993)
Florida (1403)
Georgia (305)
Hawaii (2)
Idaho (60)
Illinois (741)
India (48)
Indiana (455)
Iowa (20)
Japan (326)
Kansas (122)
Kentucky (36)
Louisiana (19)
Maine (68)
Maryland (1242)
Massachusetts (7032)
Michigan (285)
Minnesota (549)
Mississippi (4)
Missouri (112)
Montana (31)
Nebraska (25)
Nevada (103)
New Hampshire (77)
New Jersey (2621)
New Mexico (30)
New York (2558)
North Carolina (1330)
North Dakota (9)
Northern California (4406)
Ohio (288)
Oklahoma (20)
Oregon (41)
Pennsylvania (1982)
Puerto Rico (19)
Rhode Island (44)
South America (1113)
South Carolina (49)
South Dakota (1)
Southern California (3642)
Tennessee (148)
Texas (1465)
United States (34536)
Utah (280)
Virginia (228)
Washington D.C. (78)
Washington State (802)
West Virginia (4)
Wisconsin (83)
Wyoming (1)
729,694 Results for "dragonfly therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
AbTherx and Dragonfly Therapeutics Expand Antibody Discovery Partnership
September 23, 2025
·
3 min read
Genetown
Dragonfly Therapeutics, Inc. Announces Clinical Collaboration to Evaluate DF9001, an EGFR targeting TriNKET®, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors
Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, announced that it has entered into a clinical collaboration with Merck, to evaluate DF9001, Dragonfly’s EGFR immune engager, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA®, in patients with advanced solid tumors expressing EGFR.
May 21, 2024
·
3 min read
Genetown
Dragonfly Announces Clinical Collaboration Exploring Combinations of Dragonfly’s DF1001 HER-2 TriNKET® with Gilead’s Trodelvy® in two Cancer Indications
Dragonfly Therapeutics, Inc. announced a new clinical collaboration designed to evaluate and combine DF1001, a HER-2 immune engager developed using Dragonfly’s TriNKET technology platform and Dragonfly’s lead clinical asset, with Trodelvy, Gilead’s Trop-2-directed antibody drug conjugate, in metastatic breast cancer and non-small cell lung cancer.
February 15, 2024
·
3 min read
Press Releases
Vivos Inc. Strengthens Strategic Collaboration with Exubrion Therapeutics
October 30, 2025
·
2 min read
Press Releases
PreveCeutical Provides Update on Plan of Arrangement with BioGene Therapeutics Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
October 20, 2025
·
5 min read
Press Releases
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering
October 9, 2025
·
5 min read
Press Releases
Oncotelic Therapeutics Inc. (OTCQB: OTLC) at Forefront of Effort to Optimize Next-Generation Cancer Therapies
October 31, 2025
·
3 min read
Press Releases
Dragonfly Therapeutics Appoints Dr. Susan Altschuller as Chief Financial Officer
August 5, 2024
·
2 min read
Drug Development
Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303
Dragonfly Therapeutics, Inc. announced receipt of a milestone payment following dosing of the first patient in a clinical trial conducted by AbbVie to evaluate ABBV-303, a solid tumor targeting TriNKET®.
March 5, 2024
·
2 min read
Drug Development
Dragonfly Therapeutics Initiates Phase 1/1b Study of its IL-2 Immunotherapy in Patients with Advanced Solid Tumors
Dragonfly Therapeutics, Inc. today announced it recently dosed its first patient in a Phase 1/1b study of the Company’s proprietary IL-2 investigational immunotherapy, DF6215, developed for patients with advanced solid tumors.
December 5, 2023
·
3 min read
1 of 72,970
Next
